These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 26775563)

  • 21. Correlation of CYP2C19 genotype with plasma voriconazole levels: a preliminary retrospective study in Indians.
    Chawla PK; Nanday SR; Dherai AJ; Soman R; Lokhande RV; Naik PR; Ashavaid TF
    Int J Clin Pharm; 2015 Oct; 37(5):925-30. PubMed ID: 26024717
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles.
    Chung H; Lee H; Han HK; An H; Lim KS; Lee YJ; Cho JY; Yoon SH; Jang IJ; Yu KS
    Drug Des Devel Ther; 2015; 9():2609-16. PubMed ID: 25999694
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Experience of a Strategy Including CYP2C19 Preemptive Genotyping Followed by Therapeutic Drug Monitoring of Voriconazole in Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation.
    García-García I; Dapía I; Montserrat J; Martinez de Soto L; Bueno D; Díaz L; Queiruga J; Rodriguez Mariblanca A; Guerra-García P; Ramirez E; Frías J; Pérez Martínez A; Carcas-Sansuan AJ; Borobia AM
    Front Pharmacol; 2021; 12():717932. PubMed ID: 34744712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interaction of age and CYP2C19 genotypes on voriconazole steady-state trough concentration in Chinese patients.
    Du YX; Zhu YX; Li L; Yang J; Chen XP
    Pharmacogenet Genomics; 2024 Aug; 34(6):191-198. PubMed ID: 38747453
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population Pharmacokinetics of Voriconazole in Chinese Patients with Hematopoietic Stem Cell Transplantation.
    Chen C; Yang T; Li X; Ma L; Liu Y; Zhou Y; Ren H; Cui Y
    Eur J Drug Metab Pharmacokinet; 2019 Oct; 44(5):659-668. PubMed ID: 31041728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High voriconazole target-site exposure after approved sequence dosing due to nonlinear pharmacokinetics assessed by long-term microdialysis.
    Kirbs C; Kluwe F; Drescher F; Lackner E; Matzneller P; Weiss J; Zeitlinger M; Kloft C
    Eur J Pharm Sci; 2019 Apr; 131():218-229. PubMed ID: 30731238
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interpersonal Factors in the Pharmacokinetics and Pharmacodynamics of Voriconazole: Are CYP2C19 Genotypes Enough for Us to Make a Clinical Decision?
    Zhong X; Tong X; Ju Y; Du X; Li Y
    Curr Drug Metab; 2018; 19(14):1152-1158. PubMed ID: 29361899
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic drug monitoring and
    Chen X; Xiao Y; Li H; Huang Z; Gao J; Zhang X; Li Y; Van Timothee BM; Feng X
    Transl Pediatr; 2022 Aug; 11(8):1311-1322. PubMed ID: 36072540
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Frequency of the CYP2C19*17 polymorphism in a Chilean population and its effect on voriconazole plasma concentration in immunocompromised children.
    Espinoza N; Galdames J; Navea D; Farfán MJ; Salas C
    Sci Rep; 2019 Jun; 9(1):8863. PubMed ID: 31222084
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of flavin-containing monooxygenase 3 and CYP2C19 genotypes on plasma disposition and adverse effects of voriconazole administered orally in immunocompromised patients.
    Yamada T; Mino Y; Naito T; Kawakami J
    J Infect Chemother; 2019 Dec; 25(12):1019-1025. PubMed ID: 31239195
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Prospective Study on the Usefulness of Initial Voriconazole Dose Adjustment Based on CYP2C19 Gene Polymorphism Analysis.
    Tanaka R; Fujioka T; Suzuki Y; Iwao M; Itoh H
    Chemotherapy; 2020; 65(3-4):59-64. PubMed ID: 32877905
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers.
    Lee S; Kim BH; Nam WS; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    J Clin Pharmacol; 2012 Feb; 52(2):195-203. PubMed ID: 21383338
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy.
    Kadam RS; Van Den Anker JN
    Clin Pharmacokinet; 2016 Sep; 55(9):1031-43. PubMed ID: 26979736
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of CYP2C19, CYP3A4, ABCB1, and FMO3 genotypes on plasma voriconazole in Thai patients with invasive fungal infections.
    Chuwongwattana S; Jantararoungtong T; Prommas S; Medhasi S; Puangpetch A; Sukasem C
    Pharmacol Res Perspect; 2020 Dec; 8(6):e00665. PubMed ID: 33124772
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of cytochrome P450 gene polymorphism in a lupus nephritis patient in whom tacrolimus blood concentration was markedly elevated after administration of azole antifungal agents.
    Fujita Y; Araki T; Okada Y; Aomori T; Shimizu R; Tomizawa T; Hiromura K; Nojima Y; Nakamura T; Yamamoto K
    J Clin Pharm Ther; 2013 Feb; 38(1):74-6. PubMed ID: 22971159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of Physiology Based Pharmacokinetic Model to Predict the Drug Interactions of Voriconazole and Venetoclax.
    Dong J; Liu SB; Rasheduzzaman JM; Huang CR; Miao LY
    Pharm Res; 2022 Aug; 39(8):1921-1933. PubMed ID: 35725843
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of CYP2C19 Genotype and Liver Function on Voriconazole Pharmacokinetics in Renal Transplant Recipients.
    Li ZW; Peng FH; Yan M; Liang W; Liu XL; Wu YQ; Lin XB; Tan SL; Wang F; Xu P; Fang PF; Liu YP; Xiang DX; Zhang BK
    Ther Drug Monit; 2017 Aug; 39(4):422-428. PubMed ID: 28604474
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Variability of voriconazole concentrations in patients with hematopoietic stem cell transplantation and hematological malignancies: influence of loading dose, procalcitonin, and pregnane X receptor polymorphisms.
    Zeng G; Wang L; Shi L; Li H; Zhu M; Luo J; Zhang Z
    Eur J Clin Pharmacol; 2020 Apr; 76(4):515-523. PubMed ID: 31932875
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients.
    Berge M; Guillemain R; Trégouet DA; Amrein C; Boussaud V; Chevalier P; Lillo-Lelouet A; Le Beller C; Laurent-Puig P; Beaune PH; Billaud EM; Loriot MA
    Eur J Clin Pharmacol; 2011 Mar; 67(3):253-60. PubMed ID: 21038076
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population pharmacokinetics of voriconazole and the role of CYP2C19 genotype on treatment optimization in pediatric patients.
    Hu L; Huang S; Huang Q; Huang J; Feng Z; He G
    PLoS One; 2023; 18(9):e0288794. PubMed ID: 37695751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.